Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $93.3 million.

  • Cytek Biosciences' Cash & Current Investments fell 4252.66% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year decrease of 4252.66%. This contributed to the annual value of $98.7 million for FY2024, which is 4109.35% down from last year.
  • Per Cytek Biosciences' latest filing, its Cash & Current Investments stood at $93.3 million for Q3 2025, which was down 4252.66% from $75.5 million recorded in Q2 2025.
  • Cytek Biosciences' Cash & Current Investments' 5-year high stood at $376.8 million during Q3 2021, with a 5-year trough of $75.5 million in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' median Cash & Current Investments value was $173.6 million (recorded in 2024), while the average stood at $215.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 11949.21% in 2021, then tumbled by 5758.16% in 2025.
  • Cytek Biosciences' Cash & Current Investments (Quarter) stood at $364.6 million in 2021, then dropped by 17.86% to $299.5 million in 2022, then plummeted by 44.03% to $167.6 million in 2023, then plummeted by 41.09% to $98.7 million in 2024, then fell by 5.53% to $93.3 million in 2025.
  • Its Cash & Current Investments stands at $93.3 million for Q3 2025, versus $75.5 million for Q2 2025 and $95.3 million for Q1 2025.